TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Recovery of atrial mechanical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glove perforations
Endpoint domain: Adverse events/effects
Primary endpoint: Breast symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Total clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine response rates (rSBA ≥1:8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Retention of rSBA‐MenA ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events (pain, redness, fatigue)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall intubation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intubation success on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SIRT1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total metabolic syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Administered insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient satisfaction/return to work
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attachment Levels (ALs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in the function of the arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in maximal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of left‐sided cardiac valve dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Likelihood of Major Depressive Disorder (MDD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical response at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Mayo scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verbal memory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: use of compensatory strategies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: self-reported neuropsychological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meaningful relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild or no pain at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to meaningful relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iWOB reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma HIV-1 RNA levels <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: serum-free IGF-I concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need for analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS and NRS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: U-UDI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OAB-q score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived problems with activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: sense of control over fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: improved clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of the electronic version
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exact agreement percentage
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Kappa coefficients for agreement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean LV ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Supine systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cholesterol absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women recalled for assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per cancer detected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of positive thioglycolate broth cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cure rate after sclerotherapy
Endpoint domain: Mortality/survival
Primary endpoint: Pain after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: placebo analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ICTP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PICP:ICTP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 12-Step attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: consequences
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year event-free survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: grade ≥ 3 toxicity during IFN‐α‐2b treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Blood rheology and blood coagulation indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severity of skin reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PC-WUSPI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiological success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean total cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean difference in pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving optimal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma D‐dimer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vWF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-year failure-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Three-year locoregional failure-free rates
Endpoint domain: Mortality/survival
Primary endpoint: hemodynamic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gastric acid secretion suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Liver toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: One-month primary treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rates in the access closure substudy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Times to hemostasis and procedure completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: LUTS/BPH improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Q(max) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile dysfunction improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Translation between graft options
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative immunosuppression severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery of immune functions (T lymphocytes, mitogenic activity, TNF-alpha production)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Esophageal luminal temperature changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of atrioesophageal fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Serum 1,25-dihydroxyvitamin D concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Target lesion failure
Endpoint domain: Mortality/survival
Primary endpoint: Treatment completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Personal growth
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Maternal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leptin serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse obstetric and perinatal outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Birth weight (g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal height (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospitalization duration
Endpoint domain: Resource use
Primary endpoint: 2-year recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: maximal range of flexion in the hip joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: median absorption of glycine solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of decrease in serum sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful outcome rate
Endpoint domain: Mortality/survival
Primary endpoint: Edinburgh Postnatal Depression Scale (EPDS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of depression using Present State Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of mothers classified as 'borderline' or 'cases'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total DRSP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative mood score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Functional Skills Scales change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver Assistance Scales change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip abduction increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Moxifloxacin concentration in tonsillar tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue/plasma concentration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Successful voiding within 12 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improvements in subjective and objective symptoms of urinary outflow obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: systolic and diastolic blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: adverse reactions (dry mouth and dizziness)
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of TRANSFoRm system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of TRANSFoRm system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: economy of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein cholesterol (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: intraoperative and postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of GI side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: average daily GI symptom severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GI-related discontinuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Return to full time work and home activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: HRF values at the papilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unobstructed view of the glottis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness to change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Substance use goal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in the mean number of migraine days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving a 50% or greater reduction in migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of days of use of acute migraine-specific medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Mean density in the ascending aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Hygiene Index-Simplified (OHI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable cervix (Bishop score > 6 or spontaneous labor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recurrent disease
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of fundus images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative hypersensitivity (POH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating levels of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative IOP elevation in excess of 35 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: radiographic joint damage progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scheduling DFE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Obtaining DFE within 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of TI
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ADMA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Maintenance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lower-Extremity Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower-Extremity Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of tioguanine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Component Summary (MCS) score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acid-related dysmotility symptoms improvement (FSSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean surgically induced astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with workplace intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite outcome of death from any cause, new renal-replacement therapy, or persistent renal dysfunction
Endpoint domain: Mortality/survival
Primary endpoint: Analgesia success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reports of painful dental treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of dacryostenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative number of patients requiring repositioning of the tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of MPSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of MPSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fetal Growth Restriction (FGR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ipsilateral KOS-induced lacrimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of cardiovascular autonomic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in systolic blood pressure at the lying-to-standing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Valsalva manoeuvre improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body cell mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in MPIS at 3 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI at five years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: competence in nursing students for the care of oncology patients
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: diagnostic reasoning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: drinking pattern improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain responses to venepuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-proxy total quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient proxy cancer-related QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ability to regulate emotional reactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment compliance with regard to help-seeking
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: event-free survival of cardiovascular death, myocardial infarction, and recurrence of ischaemia needing repeated target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Mean tumor signal‐to‐noise ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cervical stroma signal‐to‐noise ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tumor‐to‐cervical stroma contrast‐to‐noise ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-year event-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Physical performance (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability (RMDQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac sympathetic-parasympathetic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low frequency (LF) power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High frequency (HF) power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of mebendazole against hookworm infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes